The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Vernal Keratoconjunctivitis-Global Market Insights and Sales Trends 2024
Synopsis
Vernal keratoconjunctivitis (VKC) is a rare form of chronic eye allergy of the ocular surface, and one of the most severe forms of allergic conjunctivitis. It, along with the ocular surface, causes corneal complications such as corneal scars, astigmatism and keratoconus, and if left untreated can result in vision loss. An eye-threatening disease, Vernal keratoconjunctivitis, is characterized by the swollen eyelid, tearing red eyes, mucous discharge, intense itching and photophobia. The most common symptoms of the allergy are giant papillae, superficial keratitis, limbitis, corneal epitheliopathy and conjunctival hyperaemia.
The global Vernal Keratoconjunctivitis market size is expected to reach US$ 701.8 million by 2029, growing at a CAGR of 6.5% from 2023 to 2029. The market is mainly driven by the significant applications of Vernal Keratoconjunctivitis in various end use industries. The expanding demands from the Hospital Pharmacy, Retail Pharmacy and Others,, are propelling Vernal Keratoconjunctivitis market. Topical, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Oral segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Vernal Keratoconjunctivitis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Vernal Keratoconjunctivitis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Vernal Keratoconjunctivitis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Vernal Keratoconjunctivitis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Vernal Keratoconjunctivitis covered in this report include Akari Therapeutics, Allakos, iCo Therapeutics, Santen, Senju Pharmaceutical and Alcon, etc.
The global Vernal Keratoconjunctivitis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Akari Therapeutics
Allakos
iCo Therapeutics
Santen
Senju Pharmaceutical
Alcon
Global Vernal Keratoconjunctivitis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Vernal Keratoconjunctivitis market, Segment by Type:
Topical
Oral
Global Vernal Keratoconjunctivitis market, by Application
Hospital Pharmacy
Retail Pharmacy
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Vernal Keratoconjunctivitis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Vernal keratoconjunctivitis (VKC) is a rare form of chronic eye allergy of the ocular surface, and one of the most severe forms of allergic conjunctivitis. It, along with the ocular surface, causes corneal complications such as corneal scars, astigmatism and keratoconus, and if left untreated can result in vision loss. An eye-threatening disease, Vernal keratoconjunctivitis, is characterized by the swollen eyelid, tearing red eyes, mucous discharge, intense itching and photophobia. The most common symptoms of the allergy are giant papillae, superficial keratitis, limbitis, corneal epitheliopathy and conjunctival hyperaemia.
The global Vernal Keratoconjunctivitis market size is expected to reach US$ 701.8 million by 2029, growing at a CAGR of 6.5% from 2023 to 2029. The market is mainly driven by the significant applications of Vernal Keratoconjunctivitis in various end use industries. The expanding demands from the Hospital Pharmacy, Retail Pharmacy and Others,, are propelling Vernal Keratoconjunctivitis market. Topical, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Oral segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Vernal Keratoconjunctivitis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Vernal Keratoconjunctivitis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Vernal Keratoconjunctivitis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Vernal Keratoconjunctivitis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Vernal Keratoconjunctivitis covered in this report include Akari Therapeutics, Allakos, iCo Therapeutics, Santen, Senju Pharmaceutical and Alcon, etc.
The global Vernal Keratoconjunctivitis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Akari Therapeutics
Allakos
iCo Therapeutics
Santen
Senju Pharmaceutical
Alcon
Global Vernal Keratoconjunctivitis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Vernal Keratoconjunctivitis market, Segment by Type:
Topical
Oral
Global Vernal Keratoconjunctivitis market, by Application
Hospital Pharmacy
Retail Pharmacy
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Vernal Keratoconjunctivitis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Vernal Keratoconjunctivitis
1.1 Vernal Keratoconjunctivitis Market Overview
1.1.1 Vernal Keratoconjunctivitis Product Scope
1.1.2 Vernal Keratoconjunctivitis Market Status and Outlook
1.2 Global Vernal Keratoconjunctivitis Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Vernal Keratoconjunctivitis Market Size by Region (2018-2029)
1.4 Global Vernal Keratoconjunctivitis Historic Market Size by Region (2018-2023)
1.5 Global Vernal Keratoconjunctivitis Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Vernal Keratoconjunctivitis Market Size (2018-2029)
1.6.1 North America Vernal Keratoconjunctivitis Market Size (2018-2029)
1.6.2 Europe Vernal Keratoconjunctivitis Market Size (2018-2029)
1.6.3 Asia-Pacific Vernal Keratoconjunctivitis Market Size (2018-2029)
1.6.4 Latin America Vernal Keratoconjunctivitis Market Size (2018-2029)
1.6.5 Middle East & Africa Vernal Keratoconjunctivitis Market Size (2018-2029)
2 Vernal Keratoconjunctivitis Market by Type
2.1 Introduction
2.1.1 Topical
2.1.2 Oral
2.2 Global Vernal Keratoconjunctivitis Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Vernal Keratoconjunctivitis Historic Market Size by Type (2018-2023)
2.2.2 Global Vernal Keratoconjunctivitis Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Vernal Keratoconjunctivitis Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Vernal Keratoconjunctivitis Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Vernal Keratoconjunctivitis Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Vernal Keratoconjunctivitis Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Vernal Keratoconjunctivitis Revenue Breakdown by Type (2018-2029)
3 Vernal Keratoconjunctivitis Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacy
3.1.2 Retail Pharmacy
3.1.3 Others
3.2 Global Vernal Keratoconjunctivitis Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Vernal Keratoconjunctivitis Historic Market Size by Application (2018-2023)
3.2.2 Global Vernal Keratoconjunctivitis Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Vernal Keratoconjunctivitis Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Vernal Keratoconjunctivitis Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Vernal Keratoconjunctivitis Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Vernal Keratoconjunctivitis Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Vernal Keratoconjunctivitis Revenue Breakdown by Application (2018-2029)
4 Vernal Keratoconjunctivitis Competition Analysis by Players
4.1 Global Vernal Keratoconjunctivitis Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Vernal Keratoconjunctivitis as of 2022)
4.3 Date of Key Players Enter into Vernal Keratoconjunctivitis Market
4.4 Global Top Players Vernal Keratoconjunctivitis Headquarters and Area Served
4.5 Key Players Vernal Keratoconjunctivitis Product Solution and Service
4.6 Competitive Status
4.6.1 Vernal Keratoconjunctivitis Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Akari Therapeutics
5.1.1 Akari Therapeutics Profile
5.1.2 Akari Therapeutics Main Business
5.1.3 Akari Therapeutics Vernal Keratoconjunctivitis Products, Services and Solutions
5.1.4 Akari Therapeutics Vernal Keratoconjunctivitis Revenue (US$ Million) & (2018-2023)
5.1.5 Akari Therapeutics Recent Developments
5.2 Allakos
5.2.1 Allakos Profile
5.2.2 Allakos Main Business
5.2.3 Allakos Vernal Keratoconjunctivitis Products, Services and Solutions
5.2.4 Allakos Vernal Keratoconjunctivitis Revenue (US$ Million) & (2018-2023)
5.2.5 Allakos Recent Developments
5.3 iCo Therapeutics
5.3.1 iCo Therapeutics Profile
5.3.2 iCo Therapeutics Main Business
5.3.3 iCo Therapeutics Vernal Keratoconjunctivitis Products, Services and Solutions
5.3.4 iCo Therapeutics Vernal Keratoconjunctivitis Revenue (US$ Million) & (2018-2023)
5.3.5 Santen Recent Developments
5.4 Santen
5.4.1 Santen Profile
5.4.2 Santen Main Business
5.4.3 Santen Vernal Keratoconjunctivitis Products, Services and Solutions
5.4.4 Santen Vernal Keratoconjunctivitis Revenue (US$ Million) & (2018-2023)
5.4.5 Santen Recent Developments
5.5 Senju Pharmaceutical
5.5.1 Senju Pharmaceutical Profile
5.5.2 Senju Pharmaceutical Main Business
5.5.3 Senju Pharmaceutical Vernal Keratoconjunctivitis Products, Services and Solutions
5.5.4 Senju Pharmaceutical Vernal Keratoconjunctivitis Revenue (US$ Million) & (2018-2023)
5.5.5 Senju Pharmaceutical Recent Developments
5.6 Alcon
5.6.1 Alcon Profile
5.6.2 Alcon Main Business
5.6.3 Alcon Vernal Keratoconjunctivitis Products, Services and Solutions
5.6.4 Alcon Vernal Keratoconjunctivitis Revenue (US$ Million) & (2018-2023)
5.6.5 Alcon Recent Developments
6 North America
6.1 North America Vernal Keratoconjunctivitis Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Vernal Keratoconjunctivitis Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Vernal Keratoconjunctivitis Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Vernal Keratoconjunctivitis Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Vernal Keratoconjunctivitis Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Vernal Keratoconjunctivitis Market Dynamics
11.1 Vernal Keratoconjunctivitis Industry Trends
11.2 Vernal Keratoconjunctivitis Market Drivers
11.3 Vernal Keratoconjunctivitis Market Challenges
11.4 Vernal Keratoconjunctivitis Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
